Ezetimibe and Trenbolone Interaction

Avoid
Mechanism-based 64% confidence

Ezetimibe and Trenbolone have a potentially harmful interaction with 64% confidence. Both Ezetimibe and Trenbolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

Ezetimibe

Cholesterol Absorption Inhibitor | Lipid Management On Cycle

Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle.

Half-life: ~22 hours Typical dose: 10 mg/day cardiovascular
npc1l1 hepatotoxiclipid disruptingteratogenic
View full profile

Trenbolone

19-Nor Anabolic-Androgenic Steroid | Potent Recomposition Agent

Trenbolone binds to the androgen receptor with approximately three to five times the affinity of testosterone, making it one of the strongest known AR agonists among anabolic steroids. This exceptional binding affinity drives potent activation of AR-dependent gene transcription, resulting in dramatically enhanced nitrogen retention, protein synthesis, and satellite cell proliferation in skeletal muscle.

Half-life: ~3 days (acetate) Typical dose: 200-400 mg/week anabolic
androgen receptoraromataseigf1ngf androgenicblood pressure raisingcarcinogenic riskcardiotoxic
View full profile

Combined Organ Load

Heart
moderate
Gonads
moderate
Liver
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Ezetimibe, Trenbolone). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (Ezetimibe, Trenbolone). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Ezetimibe, Trenbolone). Monitor accordingly.

Frequently Asked Questions

Can I take Ezetimibe with Trenbolone?

Combining Ezetimibe with Trenbolone is not recommended. Both Ezetimibe and Trenbolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Ezetimibe and Trenbolone safe together?

This combination carries significant risk. Both Ezetimibe and Trenbolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Ezetimibe and Trenbolone?

Both Ezetimibe and Trenbolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Ezetimibe and Trenbolone?

Ezetimibe has a half-life of ~22 hours and Trenbolone has a half-life of ~3 days (acetate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Ezetimibe vs Trenbolone

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.